Velocity Clinical Research partnered with Palantir Technologies for streamlining and automating payment reconciliation processes in trials ...

UroMems is set to enter the pivotal trial phase with its device for treating stress urinary incontinence (SUI).

Novartis is stopping the development of ianalumab in hidradenitis suppurativa (HS) after a Phase IIb proof-of-concept trial failed to meet its primary endpoint.

With the aim of being the largest life sector by 2035 behind only the US and China, the UK government is ramping up commercialisation.

The UK MHRA has granted approval for Cybin to initiate the EMBRACE study to assess CYB003 for the adjunctive treatment of MDD.

The growing prevalence of prediabetes among children and adolescents suggests that unhealthy, inactive lifestyles are increasing in the US.

World Brain Day draws attention to the increasing prevalence of Alzheimer's and PD in an ageing global population.

AstraZeneca’s anselamimab has failed to show any benefit in patients with light chain (AL) amyloidosis in two Phase III trials.

Aptar Pharma has announced the acquisition of Mod3 Pharma's clinical trial materials manufacturing capabilities from SWK Holdings.

OKYO Pharma has reported encouraging top-line outcomes from the randomised Phase II trial of urcosimod to treat NCP.

Hengrui Pharma and Kailera Therapeutics have reported positive topline data from the former’s Phase III trial (HRS9531-301) of HRS9531.

This month, the Journal of the American Medical Association (JAMA) published a collaborative article between the Children’s Hospital of Philadelphia and the University of California concerning the ...